Valeant Pharmaceuticals: Three Reasons Its New CFO is the Right Choice
August 22, 2016 at 15:18 PM EDT
Morgan Stanley's David Risinger and team offer three reasons why the appointment of Paul Herendeen as Valeant Pharmaceuticals International's ( VRX ) new CFO is a good decision :
